Novel uses of licochalcone A

A technology of licorice, disease, applied in the new use field of licochalone A, can solve the problem of no drugs, only recommended exercise and diet, etc.

Inactive Publication Date: 2014-01-29
UNIV IND COOP GRP OF KYUNG HEE UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, few drugs are available pharmacologically for the trea

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel uses of licochalcone A
  • Novel uses of licochalcone A
  • Novel uses of licochalcone A

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1: Determination of the Effects of Licochalcone A on Inhibiting Adipocyte Differentiation and Inhibiting Adipogenesis in Adipocytes

[0056] (1) Incubation of preadipocytes

[0057] 3T3-L1 preadipocytes (ATCC number: CL-173) were purchased from American type culture collection (ATCC). 3T3-L1 preadipocytes were cultured in Dalbecco's Modified Eagle's Medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS), penicillin (100 U / ml) and streptomycin (100 U / ml), 37 5%CO at ℃ 2 CO 2 cultured in an incubator.

[0058] (2) Induce differentiation into adipocytes

[0059] 3T3-L1 cells were seeded in 6-well plates and at late stage of cell confluence, treated with a hormone mix containing 0.5 mM dexamethasone, 10 μg / ml insulin and 0.5 mM IBMX (3-isobutyl-1-methylxanthine) treatment, and the medium was changed every two days. The medium was replaced with 5 μg / ml of insulin 4 days later, and then with normal medium 2 days later, thereby inducing differentiation into...

Embodiment 2

[0074] Example 2: Determination of the effect of licochalcone A on inhibiting lipogenesis and stimulating lipolysis in hepatic cells

[0075] (1) Incubation of hepatocytes

[0076] Human hepatoma HepG2 cells (ATCC number: HB-8065) ​​were purchased from the American Type Culture Collection (ATCC). HepG2 cells were cultured in Dalbecco's Modified Eagle's Medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS), penicillin (100 U / ml) and streptomycin (100 U / ml) at 37°C with 5% CO 2 CO 2 cultured in an incubator.

[0077] HepG2 cells were seeded in 6-well plates, and treated with different concentrations of licochalcone A on the next day (for 24 hours), and for different times such as 0, 6, 12 and 24 hours (with 20 μM licochalcone A processing) to obtain samples. Furthermore, to determine the correlation between AMPK activation by licochalcone A and the lipogenesis / lipolysis mechanism, samples pretreated with 10 μΜ compound C (AMPK inhibitor) from Calbiochem (Darmstadt, G...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical or food composition containing licochalcone A as an active ingredient for preventing, improving, or treating AMPK-related diseases, specifically, disorders involving lipid metabolism, hyperlipidemia, metabolic syndrome, obesity, fatty liver, or degenerative diseases (in particular, dementia). The pharmaceutical or food composition according to the present invention may significantly reduce adipocyte differentiation, adipocyte fat accumulation, and lipogenesis in hepatocytes, and may exhibit the effects of activating AMPK in hepatocytes. Accordingly, the pharmaceutical or food composition of the present invention can be effectively used for AMPK-related diseases, specifically, disorders involving lipid metabolism, hyperlipidemia, metabolic syndrome, obesity, fatty liver, or degenerative diseases (in particular, dementia).

Description

technical field [0001] The present invention relates to the new application of licochalcone A. Background technique [0002] Due to changes in lifestyle, especially increased fat intake, lack of exercise, etc., so-called "lifestyle-related diseases" such as obesity, hyperlipidemia, diabetes, and hypertension are rapidly increasing. Here, obesity is a complex syndrome involving multiple factors such as genetic, nutritional, environmental and social factors. Hyperlipidemia is an increase in the amount of cholesterol and triglycerides in the blood that occurs due to obesity, which leads to the development of high blood pressure, cardiovascular disease, stroke, and the like. In addition, excessive fat intake can lead to hepatic lipogenesis, decreased release and decomposition of triglycerides, etc., due to high blood cholesterol and fat accumulation in the body, resulting in fatty liver, which is the accumulation of fat in the liver and diseases such as arteriosclerosis Cardio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/12A61K31/05A61P25/28A61P3/06
CPCA61K31/12A23V2002/00A23L33/105A61P1/16A61P25/28A61P3/06A23V2200/332A23V2250/21A61K31/05
Inventor 郑圣显权海燕
Owner UNIV IND COOP GRP OF KYUNG HEE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products